Clinical Trial Update: A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma [Phase 2]

View source ↗

Summary

A Phase 2 study of Zanzalintinib for recurrent or metastatic olfactory neuroblastoma is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Olfactory Neuroblastoma

Drugs mentioned

• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Olfactory Neuroblastoma | Phase 2 | Status: NOT_YET_RECRUITING